NCPA: Access to controlled substances often delayed

NCPA: access to controlled substances often delayed

(HealthDay)—Most pharmacists report experiencing multiple delays or issues with their controlled substance orders, according to the results of the National Community Pharmacists Association (NCPA) Controlled Substances Access Survey.

Members of the NCPA were surveyed in December 2013 regarding pharmacy access to controlled . More than 1,000 responded to the survey, which included an open-ended section to share observations.

According to the report, in the past 18 months, about 75 percent of respondents experienced three or more delays or issues with their controlled substance orders, which were caused by stopped shipments. On average, these delays affected 55 patients per pharmacy. Most pharmacies (89 percent) received no advanced notice of the delay, and only discovered the delay when their order arrived and included only non-controlled substances. The delays in receiving these medications lasted at least a week for 60 percent of the respondents. The majority of pharmacists (67.9 percent) reported being unable to obtain these substances from an alternate source. As a result, most pharmacies had to turn patients away and refer them to a competitor.

"Vulnerable patients are increasingly and tragically becoming collateral damage in the country's battle against the abuse of prescription drugs, particularly ," Douglas Hoey, R.Ph., M.B.A., of the NCPA, said in a statement.

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

7 hours ago

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

Nov 25, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.